The BET inhibitor JQ1, along with analogs such as I-BET151 and OTX015, initially showed robust preclinical efficacy by dramatically downregulating MYC expression, resulting in significant tumor growth inhibition across diverse cancer models (Mertz et al., 2011). The gene discussed is MYC; the disease is neoplasm.